LGVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Longeveron Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.39+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $43.61M
- P/E (TTM)
- –
- Dividend yield
- –
Longeveron Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical trial revenue | $287.00K | $378.00K | $303.00K | $94.00K | $298.00K | $259.00K | $390.00K | $210.00K | $287.00K | $515.00K | $63.00K | $150.00K | 100.0% | -3.7% |
| Contract manufacturing revenue | $0 | $20.00K | $57.00K | $37.00K | $12.00K | $116.00K | $87.00K | $377.00K | $22.00K | $1.00K | – | – | 0.0% | -100.0% |
| National Institute of Health - grant [Member] | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
| Grant revenue | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
| National Institutes of Health Grant [Member] | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
| Contract manufacturing [Member] | – | – | – | – | – | – | – | $563.00K | $181.00K | $33.00K | – | – | – | – |
| Contract manufacturing lease revenue | – | – | $5.00K | $6.00K | $6.00K | $6.00K | $126.00K | $186.00K | $159.00K | $32.00K | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Longeveron's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.